GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Short Percentage of Float

InMed Pharmaceuticals (FRA:MWG0) Short Percentage of Float


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of InMed Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, InMed Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Short Percentage of Float falls into.


InMed Pharmaceuticals (FRA:MWG0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Short Percentage of Float
Comparable Companies
CWBR CNSP GMDAQ MBIO ARDS PXMD SCNI ELOX GLMD SLRX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
INM:USA MWG0:Germany
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
Website
https://www.inmedpharma.com
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines